An expanded access record providing Pelacarsen in Atherosclerotic Cardiovascular Disease, ASCVD, sponsored by Novartis Pharmaceuticals. Available. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-18.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Expanded access
The purpose of this registration is to list Managed Access Programs (MAPs) related to TQJ230, pelacarsen
CTQJ230A12013M - Available - Managed Access Program (MAP) Cohort Treatment Plan (CTQJ230A12013M) to provide access to pelacarsen (TQJ230) for (Atherosclerotic Cardiovascular Disease, ASCVD)
1,568 studies on the registry are indexed under Atherosclerosis; 264 are open to participants now.
Browse Atherosclerosis studies →Novartis Pharmaceuticals is the lead sponsor of 2,673 studies on the registry; 228 are open to participants now.
Of its 576 completed or terminated interventional studies of FDA-regulated products, 431 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Patients receive Pelacarsen
Also known as: TQJ230
No study locations are listed for this record.
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
Contact the providerGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.